ENHERTU is now approved for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.1

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon
verification and description of clinical benefit in a confirmatory trial.1


NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include fam-trastuzumab deruxtecan-nxki (ENHERTU®) as a Category 2A
recommendation for HER2-mutant 2L mNSCLC2,a

aFam-trastuzumab deruxtecan-nxki (ENHERTU®) is recommended (Category 2A) as a 2L or subsequent therapy for HER2-mutant non-squamous NSCLC for unresectable locally advanced, recurrent or metastatic disease. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. For detailed recommendations, see the NCCN Guidelines® for Non-Small Cell Lung Cancer at

2L, second line; ERBB2, erb-b2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; mNSCLC, metastatic non-small cell lung cancer; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer.